[
  {
    "criterion": "Mentions the risk of PML associated with natalizumab",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Provides a clear definition of PML",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Incorrectly states that JC-virus is always present in patients with MS",
    "axis": "accuracy",
    "point": -7
  },
  {
    "criterion": "Asks the user to clarify their question about bridging therapy",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Uses technical jargon without explanation, making it difficult for non-experts to understand",
    "axis": "communication_quality",
    "point": -5
  },
  {
    "criterion": "Correctly describes the concept of bridging therapy",
    "axis": "completeness",
    "point": 10
  },
  {
    "criterion": "Mentions the importance of considering individual patient factors when transitioning from natalizumab to ocrelizumab",
    "axis": "context_awareness",
    "point": 8
  },
  {
    "criterion": "Does not provide any information about the recommended duration of bridging therapy",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Incorrectly states that ocrelizumab is a suitable alternative to natalizumab for all patients",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Provides a clear explanation of the bridging therapy concept, including the potential risks and benefits",
    "axis": "completeness",
    "point": 9
  }
]